Please contact our sales representative to learn more information about this reagents.
Background
Tigatuzumab (CS-1008) is a monoclonal antibod for the treatment of cancer. As of October 2009, a clinical trial for the treatment of pancreatic cancer, Phase II trials for colorectal cancer, non-small cell lung cancer, and ovarian cancer have been completed.